IRGC1 Inhibitors
IRGC1 inhibitors belong to a class of chemical compounds that specifically target the activity of the interferon-regulated GTPase 1 (IRGC1) protein. IRGC1 is a member of the GTPase family, a group of enzymes that hydrolyze GTP to GDP, playing an important role in various cellular functions such as signal transduction, protein synthesis, and cell differentiation. The primary role of IRGC1 is thought to be associated with immune response modulation, particularly in the context of pathogen recognition and response, although its exact molecular functions remain an area of active study. Inhibitors of IRGC1 are designed to selectively bind to the protein and inhibit its GTPase activity, thereby modulating downstream signaling pathways associated with immune and cellular regulation. The structural specificity of these inhibitors often revolves around mimicking or blocking the GTP-binding site, or they may allosterically alter the conformation of IRGC1, rendering it inactive.
The chemical structures of IRGC1 inhibitors are diverse, ranging from small molecules to more complex structures capable of penetrating cells and interacting with their target protein. These inhibitors are typically designed to maintain a high degree of specificity for IRGC1, minimizing off-target effects on other GTPase family members. This selectivity is crucial for dissecting the biological pathways in which IRGC1 is involved and for studying its role in cellular processes such as immune signaling and autophagy. In terms of biochemical properties, IRGC1 inhibitors often exhibit strong binding affinity to their target, a low dissociation rate, and a favorable pharmacodynamic profile within controlled experimental settings. Understanding the molecular interactions between IRGC1 and its inhibitors contributes significantly to advancements in biochemical research focused on the regulatory mechanisms of immune response and GTPase-associated cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin acts as a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators of the AKT signaling pathway. IRGC1 function could be compromised through the inhibition of PI3K, as this would lead to decreased AKT activation and subsequent downstream signaling events critical for IRGC1's role in cellular processes such as metabolism and survival. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another specific inhibitor of PI3K, similar to Wortmannin, but with a different chemical structure. By inhibiting PI3K, LY294002 can decrease AKT phosphorylation and activity. Reduced AKT activity can lead to a lower functional activity of IRGC1 if IRGC1 activity is dependent on the PI3K-AKT signaling axis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor and can suppress the mTOR pathway, which is involved in cell growth and proliferation. If IRGC1's function is linked to mTOR signaling, the inhibition of mTOR by Rapamycin would lead to decreased IRGC1 activity as a result of reduced protein synthesis and cell growth signals. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 specifically inhibits MEK1/2 within the MAPK/ERK pathway. This pathway is implicated in cell proliferation and differentiation. If IRGC1 is regulated by or interacts with components of the MAPK/ERK pathway, inhibition of MEK would lead to decreased ERK activation and a consequent reduction in IRGC1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, a kinase involved in the response to stress signals and inflammatory cytokines. If IRGC1 is activated by or acts downstream of p38 MAPK signaling, inhibition by SB203580 would result in decreased activation of IRGC1 due to impaired stress or cytokine-induced signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also a MEK inhibitor that blocks the MAPK/ERK pathway. By inhibiting MEK, U0126 would prevent the activation of ERK and its downstream targets. This would lead to decreased IRGC1 activity if IRGC1 relies on the MAPK/ERK pathway for its regulation or is part of this signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK) pathway, which is activated by stress and inflammatory signals. IRGC1 activity could be suppressed by SP600125 if IRGC1 is regulated by JNK signaling or is implicated in cellular responses that involve JNK activation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a potent inhibitor of Src family kinases, which are involved in various signaling pathways that regulate cell proliferation, differentiation, and survival. If IRGC1 depends on Src kinase signaling for its activity, inhibition by PP2 would lead to decreased IRGC1 activity due to the disruption of these signaling pathways. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is an inhibitor of the activin receptor-like kinase (ALK) receptors, which are part of the TGF-β receptor complex. Although TGF-β itself was excluded, ALK inhibition by SB431542 can lead to decreased SMAD phosphorylation and signaling. If IRGC1 function is SMAD-dependent, then its activity would be reduced by SB431542. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor which prevents the degradation of ubiquitinated proteins. If IRGC1 function is connected with the degradation of regulatory proteins by the proteasome, inhibition by Bortezomib could lead to an accumulation of such proteins, resulting in altered IRGC1 activity due to disrupted protein turnover. | ||||||